Home > Boards > US OTC > Medical - Drugs > Roche Holding Ltd. (RHHBY)

Roche and Labcyte Integrate Echo and LightCycler Systems

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
SAE Member Profile
 
Followed By 2
Posts 564
Boards Moderated 0
Alias Born 08/06/09
160x600 placeholder
FDA panel votes to keep indications for Merck, Roche bladder cancer drugs Seeking Alpha - 4/30/2021 7:58:15 AM
FDA panel votes to maintain breast cancer indication for Roche's Tecentriq Seeking Alpha - 4/27/2021 5:26:34 PM
Roche Gets FDA Approval for Cancer-Treatment Test Dow Jones News - 4/23/2021 6:47:00 AM
Roche Q1 sales beats forecast, 2021 outlook confirmed Seeking Alpha - 4/21/2021 5:35:48 AM
Roche Holding beats on revenue; 2021 outlook confirmed Seeking Alpha - 4/21/2021 4:43:18 AM
Roche Backs 2021 Views After 1Q Sales Fall Slightly Dow Jones News - 4/21/2021 1:54:00 AM
Novartis to help produce Roche's Actemra Seeking Alpha - 4/15/2021 5:38:12 AM
Roche’s Evrysdi continues to improve motor function, survival in babies with spinal muscular atrophy Seeking Alpha - 4/15/2021 3:11:36 AM
Novartis Enters Agreement With Roche on Production of the Latter's Drug Dow Jones News - 4/15/2021 2:14:00 AM
Roche's Spark in Gene-Therapy Collaboration With Senti Bio Dow Jones News - 4/13/2021 10:10:00 AM
Roche unit Spark Therapeutics inks deal to bolster gene therapy research platform Seeking Alpha - 4/13/2021 9:16:17 AM
Novartis, Genentech Get FDA OK of Self-Administered Xolair Dow Jones News - 4/12/2021 2:12:00 PM
Roche's Phase 3 Trial of Casirivimab, Imdevimab Shows Cut Risk of Symptomatic Covid-19 Infections Dow Jones News - 4/12/2021 1:52:00 AM
Roche's Elecsys COVID-19 antibody test now available in Canada Seeking Alpha - 4/6/2021 8:41:03 AM
PTC Therapeutics earns $20M milestone under Evrysdi deal with Roche Seeking Alpha - 4/1/2021 8:34:57 AM
Roche, PTC Therapeutics Gets European OK of Evrysdi in Spinal Muscular Atrophy Dow Jones News - 3/30/2021 6:56:00 AM
iTeos Therapeutics shares rise 4% as Wedbush ups price target Seeking Alpha - 3/25/2021 4:19:31 PM
Ixico Shares Fall as Roche Halts Huntington's Disease Trial Dow Jones News - 3/23/2021 11:59:00 AM
Ionis Pharmaceuticals Partner Stops Dosing in Huntington's Disease Study Dow Jones News - 3/23/2021 7:15:00 AM
Roche Covid-19 Antibody Trial Meets Primary Endpoint Dow Jones News - 3/23/2021 2:50:00 AM
Genentech: Dosing to Stop in Phase III Clinical Study of Tominersen Dow Jones News - 3/22/2021 4:58:00 PM
Ionis announces discontinuation of Huntington's disease studies Seeking Alpha - 3/22/2021 4:39:33 PM
Genentech's Tecentriq meets late-stage lung cancer study main goal Seeking Alpha - 3/22/2021 6:29:16 AM
Roche's Tecentriq Meets Primary Endpoint in Phase 3 Lung Cancer Study Dow Jones News - 3/22/2021 2:45:00 AM
Artelo Biosciences Shares Rise 8% on Acceptance Into U.K Oncology Program Dow Jones News - 3/19/2021 10:49:00 AM
SAE   Tuesday, 12/06/11 12:25:28 PM
Re: None
Post # of 252 
Roche and Labcyte Integrate Echo and LightCycler Systems to Increase Performance of qPCR-based RNA/DNA Analyses

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Labcyte Inc. will cooperate around high-speed, miniaturized quantitative PCR (qPCR) to monitor the expression of tens to thousands of genes for therapeutic research.

The RealTime ready Cell Lysis kit from Roche enables gene expression directly from cell lysates. Coupled with Echo® liquid handlers and newly-released tissue culture microplates from Labcyte, researchers can greatly simplify high-throughput qPCR analyses. This process can be fully automated using the Access™ Workstation from Labcyte which integrates the Echo liquid handler with either the LightCycler 480 or LightCycler 1536 Instrument. Gene expression profiles derived in a one-step process directly from cells can now be streamlined into a simple automated workflow, significantly increasing productivity.

“The LightCycler 480 and 1536 Systems are designed for high-throughput gene detection, gene expression, and genetic variation analysis. Unlike other high throughput systems on the market that offer greater than 384 well capability, the Lightcycler 1536 allows for individual well to well addressability and optimization due to its true qPCR nature,” said Dr. Matthias Hinzpeter, Project Leader qPCR/NAP Systems. “This integrated platform reduces data costs associated with gene expression profiling, allowing efficient incorporation of qPCR into the early stages of drug discovery.”

“The Echo liquid handlers use acoustic energy to transfer precise nanoliter volumes of samples, primers, probes and real-time PCR reagents,” said Stephen Bates, Labcyte Senior Vice President. “Our patented acoustic dispensing eliminates the need for pipette tips and completely removes the risk of cross contamination. The simplicity of plate reformatting and cherry picking features in our Echo software applications suite maximizes PCR layout flexibility without fixed format constraints.”

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

About Labcyte

Labcyte, a global biotechnology tools company headquartered in Sunnyvale, California, is revolutionizing liquid handling. Echo liquid handling systems use sound to precisely transfer liquids. Labcyte instruments are used worldwide by all ten of the top ten pharmaceutical companies, as well as by small to mid-size pharmaceutical companies, biotechnology firms, contract research organizations and academic institutions. Labcyte’s customers work across a wide spectrum of biology including drug discovery, genomics, proteomics, diagnostics, imaging mass spectrometry and live cell transfer. Labcyte has 44 U.S., 8 European, 5 Japanese and 1 Chinese patents with additional U.S. and international filings. For more information, visit www.labcyte.com.

For life science research only. Not for use in diagnostic procedures.

LIGHTCYCLER and REALTIME READY are trademarks of Roche.

Echo and Access are trademarks of Labcyte Inc.

All other product names and trademarks are the property of their respective owners.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50094307&lang=en



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences